Project description
Solution for PTSD is a breakthrough in mental healthcare
The burden of post-traumatic stress disorder (PTSD) weighs heavily on countless individuals, affecting their daily lives and mental well-being. Traditional treatments often come with adverse side effects, leaving patients searching for more effective and tolerable solutions. With this in mind, ReST Therapeutics, a French biotech company, launched the EIC-funded FENM4PTSD project with the objective to develop innovative therapies. Targeting complex central nervous system disorders like PTSD, the project aims to revolutionise treatment methods and provide hope to those grappling with the debilitating effects of PTSD. Their lead candidate, the neuroprotective drug FENM, holds the promise of offering relief without the drawbacks of current options, marking a significant step forward in mental healthcare.
Objective
ReST Therapeutics is a French biotech company founded late 2020 that develops breakthrough therapies to treat complex central nervous system disorders, in particular, Post-Traumatic Stress Disorder (PTSD) under its various forms followed by Alzheimer Disease (AD).
Our lead candidate - FENM is a novel and proprietary chemical entity (NCE) targeting specifically a subtype of NMDA receptor (involved in synaptic plasticity) in order to facilitate stress release and neuroprotection without triggering adverse side effects of current NMDA targeting drugs. FENM will enter First-in-Human in June 2023 to initiate the clinical demonstration on PTSD.
ReST is also advancing new compounds to generate a robust library of candidates and generalize its NMDAr subtype modulation platform with the potential to treat other neurologic disorders. With the EIC support, ReST will bring FENM to clinical PoC (PhIIb) by 2027, secure a partnership with a pharma company and develop new small molecules to expand its pipeline.
Fields of science
Keywords
Programme(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Funding Scheme
HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended FinanceCoordinator
75006 PARIS
France
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.